Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Healthcare Aktiengesellschaft

Bayer Schering Pharma Ag

Hanna Tinel

Carsten Schmeck

Peter Kolkhof

Raimund Kast

Heiko Schirmer

Alexander Straub

Elisabeth Pook

Chantal Fürstner

Thomas Neubauer

Frank Wunder

Pierre Wasnaire

Dieter Lang

Klemens Lustig

Anja Buchmüller

Katja Zimmermann

Heinrich Meier

Jens Ackerstaff

Chantal Fuerstner

Adrian Tersteegen

Martina Schäfer

Axel Kretschmer

Philipp Buchgraber

Andreas Knorr

Alexandros Vakalopoulos

Michael Hahn

Gorden Redlich

Walter Hübsch

Joerg Keldenich

Eva-Maria Becker

Tobias Marquardt

Johannes-Peter Stasch

Markus Follmann

Joachim Mittendorf

Martina Delbeck

Anne-Sophie Rebstock

Karl-Heinz Schlemmer

Peter Fey

Walter Hubsch

Joachim Schuhmacher

Thomas Ernst Müller

Lars Bärfacker

Bernd Riedl

Matthias Beat Wittwer

Thomas Mondritzki

Dmitry Zubov

Eva Maria Becker-Pelster

Jens Schamberger

Karen Engel

Marie-Pierre Collin-Kroepelin

Herbert Himmel

Andreas Göller

Hana Cernecka

Henrik Teller

Kirsten Börngen

Ildiko Terebesi

Volker Geiss

Melissa Boultadakis Arapinis

Markus Brechmann

Klaus Münter

Karoline Dröbner

Marie-Pierre Collin

René Martin

Till Freudenberger

Maximillian Andreas Kullmann

Anja Buchmueller

Niels Lindner

Johannes Köbberling

Britta Olenik

Gunter Karig

Andreas Wilmen

Haruka Shimizu

Michael Härter

Ursula Krenz

Lisa Dietz

Birgit Keil

Christoph Freiberg

Andreas Ohm

Mark Meininghaus

Peter Sandner

Mark Trautwein

Katrin Nowak-Reppel

Lars Linden

Martina Klein

Karoline Droebner

Marie-Pierre Collin-Kröpelin

Klaus Benke

Ulrich Haupts

Norbert Witowski

Clemens Bothe

Guido Becker

Julian Egger

Joachim Hütter

Arnel B Concepcion

Eva-Maria Becker-Pelster

Friedrich Grimminger

Annett Richter

Bernd Rösler

Thomas Müller

Helene Faber

The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension with idiopathic interstitial pneumonia (PH-IIP), characterized in that an inhalative dosage form comprising 240 to 4000 μg, preferably 480 to 2000 μg of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid of formula (I), preferably in form of one of its salts or solvates or hydrates, preferably in form of monohydrate I of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxy lie acid in form of mono hydrate (II) of formula (I-M-II), is administered to a patient in need thereof once or twice daily for a period of at least two consecutive days, preferably at least 2 to 7 consecutive days, preferably for a period of at least 14 consecutive days, in particular from after onset of treatment for the whole course of the disease, wherein the inhalative dosage form preferably comprises the combination of the active ingredient and a pharmaceutically suitable excipient or carrier, while preferably the active ingredient and a pharmaceutically suitable excipient are filled in a hard capsule.

Treatment of cardiopulmonary disorders

The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof

The present invention relates to novel amine substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Amine substituted triazole derivatives and uses thereof

The present invention relates to prodrugs of 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[3-(trifluoromethyl)-pyridin-2-yl ]-1H-1,2,4-triazole-5-carboxamide, 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(trifluoromethyl)-phenyl]-1H-1,2,4-triazole-5-carboxamide and 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-(3-chloropyridin-2-yl)-1H-1,2,4-triazole-5-carboxamide, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Prodrugs of substituted triazole derivatives and uses thereof

The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Substituted triazole derivatives and uses thereof

The present invention relates to novel 5-(carboxamide)-1-pyridinyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Amide-substituted pyridinyltriazole derivatives and uses thereof

The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

Substituted piperidinyl tetrahydroquinolines

The present invention relates to novel 5-(carboxamide)-1-phenyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Amide-substituted phenyltriazole derivatives and uses thereof

The present invention relates to novel 5-(hydroxyalkyl)-1-heteroaryl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof

The present application relates to novel 7-substituted 1-pyridylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.

7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof

The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

Positive allosteric modulators of muscarinic M2 receptor

Growing community of inventors

Wuppertal, Germany

Hanna Tinel